Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as new Chief Medical Officer amid clinical advances.

Eupraxia Pharmaceuticals appointed Dr. Jeymi Tambiah as its new Chief Medical Officer, succeeding Dr. Mark Kowalski who is retiring. Dr. Tambiah brings over 18 years of experience in clinical development and medical strategy, expected to strengthen Eupraxia's leadership as it advances its EP-104GI treatment for Eosinophilic Esophagitis and expands its gastroenterology pipeline. Eupraxia's proprietary Diffusphere™ technology aims to improve drug delivery and reduce side effects. The company is currently conducting clinical trials for EP-104GI and other long-acting formulations targeting inflammatory and oncology indications.